Symphera
Symphera GmbH is a Munich-based pre-clinical medtech company developing an all-in-one surgical system that automates instrument switching during laparoscopic procedures, targeting hospital surgical departments with an integrated investigational device.
- Company typePrivate
- Founded2023
- HeadquartersMünchen, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Symphera does
Symphera GmbH is a Munich-based medical technology company developing an all-in-one surgical system that automates instrument switching during laparoscopic minimally invasive procedures. The platform consolidates multiple discrete laparoscopic tools into a single integrated device featuring a multifunctional tool-tip, enabling automated in-body instrument changes at the push of a button. This design is intended to replace the 20 to 50 manual tool exchanges typical of conventional laparoscopic workflows, with the stated aim of reducing procedure time (an estimated up to 20% of surgery time is currently consumed by tool changes) and improving surgeon focus, workflow continuity, and patient safety. The product is positioned for hospital surgical departments performing the estimated 15 million laparoscopic procedures performed annually worldwide.
The Symphera System is an investigational device that has not been cleared or approved by the FDA or any other regulatory authority and is not commercially available. To date, the company has demonstrated pre-clinical usability at IRCAD and published peer-reviewed animal-tissue research in Surgical Endoscopy in collaboration with Prof. Jacques Marescaux. In April 2025, the system was accepted into the FDA's Safer Technologies Program (STeP), providing an expedited US regulatory pathway. The company is not yet generating revenue and has not disclosed a pricing model, with unit economics intended to be defined following regulatory clearance; the intended go-to-market appears to be a capital equipment sale to hospital surgical departments.
Symphera is a privately held German GmbH founded as a spinoff of the "Viable Surgery" project incubated under Germany's EXIST program. It has raised a €2.4 million seed round in August 2024 led by High-Tech Gründerfonds (HTGF) with participation from Bayern Kapital, Carma Fund, IRCAD, Stern Stewart Ventures, and UnternehmerTUM, followed by an EIC Accelerator grant from the European Innovation Council in June 2025. The four co-founders — Conrad Heid, Thomas Wegele, Nico Weigand, and Philipp Preißler — lead a small team of 1–10 employees and have added Dr. Brett Parker of Johns Hopkins as a clinical advisor.
Symphera firmographics
Firmographics- Name
- Symphera
- Legal name
- Symphera GmbH
- Website
- https://symphera.io
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Symphera GmbH is a Munich-based pre-clinical medtech company developing an all-in-one surgical system that automates instrument switching during laparoscopic procedures, targeting hospital surgical departments with an integrated investigational device.
- Ownership category
- akta.pro rank
Symphera industry classification
Industry- Product category
- Minimally Invasive Surgical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity) (HLAHADAE)
- akta.pro secondary industries
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
Keywords
Where Symphera is headquartered
LocationHeadquarters
- HQ city
- München
- HQ country
- Germany
- HQ region
- Europe
Markets served
Symphera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pre-revenue (investigational device): Symphera explicitly states that "The Symphera System is an investigational device, not cleared or approved by the FDA or any regulatory authority, and not available for commercial use." The company is currently funded by grants and equity (HTGF seed round, EIC Accelerator grant, EXIST program) rather than product sales. No commercial revenue stream is disclosed.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Not publicly disclosed — investigational device only |
Go-to-market motion3 records
Symphera product offering
Product offeringCore offering
Symphera is developing an all-in-one surgical system for minimally invasive (laparoscopic) procedures that integrates multiple separate laparoscopic tools into a single device, enabling automated in-body instrument switching at the push of a button. The platform is intended to replace the manual exchange of 20–50 tools per procedure, giving surgeons uninterrupted control, autonomy, safety, and efficiency in the operating room. The system is currently an investigational device, not yet cleared or approved by the FDA or any regulatory authority, and is not available for commercial use.
Differentiator
Problem solved
Functional benefit
Products and services
- Symphera System (all-in-one surgical system)
Companies that use Symphera
Customer profileIdeal customer profiles1 record
Symphera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Symphera partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Symphera competitors and assessment
Company assessmentBroad incumbents
- Stryker: Large diversified medtech company with the Mako robotic surgery system and a broad surgical instruments portfolio. A broad incumbent peer overlapping in surgical robotics and laparoscopic instrumentation, with significantly more resources and hospital reach.
- Intuitive Surgical: Developer of the da Vinci surgical system, the dominant robotic-assisted minimally invasive surgery platform. Directly comparable as a minimally invasive surgical device competitor targeting the same laparoscopic procedure volumes, though Intuitive operates a much broader and more established platform.
- Johnson & Johnson MedTech: Healthcare giant developing the Ottava robotic-assisted surgery system and a broad minimally invasive surgery portfolio. A broad incumbent peer in surgical robotics and laparoscopic devices with the resources to define hospital standards.
- Medtronic: Global medical device leader that has launched the Hugo robotic-assisted surgery system targeting laparoscopic procedures. A broad incumbent peer competing in the same minimally invasive surgery category with far greater capital and a broad surgical portfolio.
Direct peers
- Distalmotion: Swiss developer of the Dexter surgical robot designed to bring robotic assistance to laparoscopic procedures. Directly comparable as a European, venture-backed surgical robotics startup targeting hospital adoption in minimally invasive surgery.
- Moon Surgical: Paris-based developer of a robotic-assisted laparoscopic platform that works alongside existing surgical tools. Comparable to Symphera as an emerging surgical robotics company targeting efficiency and workflow improvements in laparoscopic operating rooms.
- Asensus Surgical: US-listed company developing the Senhance laparoscopic robotic platform with a focus on digitizing and enhancing minimally invasive surgery. A direct peer competing in laparoscopic surgical robotics and digital surgery workflows.
- CMR Surgical: UK-based developer of the Versius surgical robotic system for laparoscopic procedures. A direct peer: a smaller, venture-backed surgical robotics company focused specifically on minimally invasive laparoscopic surgery, competing for the same hospital and surgeon customers as Symphera.
Emerging players
- EndoQuest Robotics: Developer of an endoluminal robotic system for flexible endoscopy procedures. An emerging peer operating at the intersection of minimally invasive surgery and robotics, adjacent to Symphera's stated expansion interest in therapeutic endoscopy.
- Vicarious Surgical: US-based developer of a next-generation robotic surgical platform combining virtual reality and miniature robotics. An emerging peer in surgical robotics with a comparable early-stage profile and focus on minimally invasive procedures.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
Symphera social profiles
Digital presenceSymphera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Symphera leadership team
Management profileNumber of profiles
Profiles5 records
Symphera funding detail
Funding detailFunding overview
Funding rounds3 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Symphera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Symphera
What does Symphera do?
Symphera is developing an all-in-one surgical system for minimally invasive (laparoscopic) procedures that integrates multiple separate laparoscopic tools into a single device, enabling automated in-body instrument switching at the push of a button. The platform is intended to replace the manual exchange of 20–50 tools per procedure, giving surgeons uninterrupted control, autonomy, safety, and efficiency in the operating room. The system is currently an investigational device, not yet cleared or approved by the FDA or any regulatory authority, and is not available for commercial use.
Is Symphera a public or private company?
Symphera is a private company. It is classified as venture growth investor backed and is currently operating.
When was Symphera founded?
Symphera was founded in 2023. It employs 1 to 10 people.
Where is Symphera based?
Symphera is headquartered in München, Germany, in the Europe region.
How does Symphera make money?
One revenue line is on record: pre-revenue (investigational device).
Who are Symphera's main competitors?
Broad incumbents on record are Stryker, Intuitive Surgical, Johnson & Johnson MedTech and Medtronic. Direct peers are Distalmotion, Moon Surgical, Asensus Surgical and CMR Surgical. Emerging players are EndoQuest Robotics and Vicarious Surgical.
Does Symphera have an API?
No public API is recorded for Symphera.
What industry is Symphera in?
Symphera's product category is Minimally Invasive Surgical Devices. Its primary akta.pro industry code is HLAHADAE, Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity), with a secondary code of HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms. Its NAICS code is 339112 and its SIC code is 3841.